Compare Neurocrine Biosciences Inc (NBIX) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Riot Platforms Inc — how do they compare? Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B), while Riot Platforms Inc trades at $16.89 (market cap $6.32B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.3× Riot Platforms Inc's market cap, and Riot Platforms Inc is more actively traded (30,571,756 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Riot Platforms Inc for 16 Days on average.
| NBIX | RIOT | |
|---|---|---|
Market Cap | $14.36B | $6.32B |
Volume | 1,237,180 | 30,571,756 |
Sector | Health | Financials |
52-Week High | $185.50 | $28.67 |
52-Week Low | $123.10 | $11.83 |
Typical Hold Time | 23 Days | 16 Days |
Enterprise Value | $14.37B | $6.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
RIOT Platforms trades at $16.885, down 8.93% on the day, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported significant losses with a net income margin of -196.28% in 2026, though revenue grew to $675 million. Recent strategic shifts toward AI data center leasing, including a $9.1 billion contract, highlight transformation efforts amid challenging profitability.
While analyst consensus remains strongly bullish with a $31.64 price target, substantial execution risks and persistent negative earnings pose challenges. The stock's outlook hinges on successful monetization of AI infrastructure contracts and improved operational efficiency to stem cash flow deficits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
